the biotechnology juggernaut Vertex Pharmaceuticals, has positioned it as an important, non-opioid option for pain management. While doctors have welcomed this additional tool, and some analysts ...

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

FDA approval of a novel non-opioid analgesic will hopefully address the needs of many patients with acute pain and improve ...

While it wasn’t found to be superior to that standard therapy for acute pain in both trials, Vertex’s drug offers the possibility to “fill the gap between medicines with good tolerability ...

Its shares slipped by 15% in December after the firm’s non-opioid pain drug failed to impress investors. Cramer’s previous remarks about Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ...

The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...

Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The ...

The equity portion of the Abrdn Healthcare Investors Fund fell (gross of fees) but outperformed its custom benchmark over the ...

The non-opioid nature of Journavx is expected to be a key differentiator in a market that is increasingly seeking alternatives to traditional opioid-based pain medications. Vertex’s pipeline ...